B+
Bull case
25%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
EOLS
EvolusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Commercial momentum is improving, with 21% Q2 revenue growth, positive adjusted EBITDA, market-share gains, expanding Evolysse adoption, and a raised 2026 outlook [#SEC-8K-2026-08-05].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.4.
What can break
Cash declined from $49.8 million at Q1-end to $45.2 million at Q2-end while the company continues investing in expansion.
Momentum
95
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.60 · Bull $11.50 · Bear $7.00Analysis 2026-08-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.00
Why
Momentum95 · Δ7d +2.3
Value41 · Δ7d 0.0
Sentiment76 · Δ7d +9.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +9.4.
Contradictions & invalidation
- • Cash declined from $49.8 million at Q1-end to $45.2 million at Q2-end while the company continues investing in expansion.
- • Evolysse Sculpt approval could be delayed or not achieved [#SEC-8K-2026-05-04].
- • The company remains GAAP-loss-making, cash declined during Q2, tariff uncertainty persists, and key portfolio expansion depends on regulatory and development milestones with long timelines.
Catalyst clock
2026-08-31
Q2 execution and raised FY2026 outlook
Lead driver: Sentiment · See AI snapshot
Momentum
95
9% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
+2.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
76
62% active weight
Current posture
7d trendImproving
Δ7d
+9.4
Δ21d
-14.8
Why this grade
Composite grade B. Momentum 95.2 / Value 41.2 / Sentiment 75.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$9.60
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$513.21M
Beta
1.12
Shares Out
66.05M
P/E (TTM) · Derived
-9.7
P/S (TTM)
1.37
P/FCF (TTM) · Derived
-27.56
Rev YoY
+21.2%
EPS YoY
-54.0%
Gross Margin
+64.9%
Op Margin
-6.5%
Net Debt
$101.17M
Current Ratio
1.70
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data